Summary
Walvax Biotechnology Co., Ltd. (Walvax) is a biopharmaceutical company that researches, develops, produces and markets a range of bio-medical products. Its products include Haemophilus influenzae vaccine for the prevention of infectious diseases such as meningitis, pneumonia, septicemia, cellulitis, arthritis and epiglottitis; Group A, C meningococcal polysaccharide vaccine for preventing diseases such as cerebrospinal meningitis and septicemia; and Group ACYW135 meningococcal polysaccharide vaccine to prevent meningococcal disease. Walvax offers its products through a distribution network in China and other counties. The company operates a research and development center in Kunming and has production units in Yunnan Yuxi and Jiangsu Taizhou. Walvax is headquartered in Kunming, China.
Walvax Biotechnology Co., Ltd. (300142) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Walvax Biotechnology Co., Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Walvax Biotechnology Co., Ltd., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Walvax Biotechnology Co., Ltd., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Walvax Biotechnology Co., Ltd., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Walvax Biotechnology Co., Ltd., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Walvax Biotechnology Co., Ltd., Pharmaceuticals & Healthcare, Deal Details 11
Equity Offering 11
Walvax Biotech Plans to Raise up to USD72.9 Million in Private Placement of Shares 11
Debt Offering 12
Walvax Biotechnology Announces Public Offering Of Notes For US$188 Million 12
Walvax Biotechnology Plans Debt Offering For US$398 Million 13
Walvax Biotechnology Announces Public Offering Of Bonds For US$158 Million 14
Acquisition 15
Walvax Biotech to Divest Kerry and Bio-Pharma and Heyzer Run Biotech for USD82 Million 15
Walvax Biotech to Sell 46% Stake in Hebei Da'an Pharma for USD103 Million 16
Walvax Biotech Plans to Acquire 51% Stake in Chongqing times Ning for USD29 Million 17
Walvax Biotech Receives Approval to Acquire Chongqing Beining Biological Pharma for USD57 Million 18
Walvax Biotech Acquires Three Biomedical Companies 19
Walvax Biotechnology To Acquire 63.57% Stake In Genor BioPharma From Shihezi Ansheng Investment And Wison Group For US$47.5 Million 20
Walvax Biotechnology To Acquire Ningbo Biological Medicine Company For US$48.5 Million 22
Walvax Biotechnology To Acquire Putian Pharma Company For US$26.3 Million 23
Walvax Biotechnology To Acquire Shandong Biological Medicine Company For US$48.5 Million 24
Walvax Biotechnology Acquires 40.61% Stake In Shanghai Biotech Company For US$19.7 Million 25
Walvax Biotechnology To Acquire Additional 35% Stake In Hebei Da'an Pharma For US$54.6 Million 26
Yunnan Walvax Acquires 58% Stake In Shanghai Zerun Biotech For US$49 Million 27
Walvax Biotechnology Completes Acquisition Of 55% Stake In Hebei Da'an Pharma For Up To US$84 Million 29
Walvax Biotechnology Co., Ltd. - Key Competitors 30
Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32
List of Tables
Walvax Biotechnology Co., Ltd., Pharmaceuticals & Healthcare, Key Facts, 2014 1
Walvax Biotechnology Co., Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Walvax Biotechnology Co., Ltd., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Walvax Biotechnology Co., Ltd., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Walvax Biotechnology Co., Ltd., Deals By Therapy Area, 2010 to YTD 2016 8
Walvax Biotechnology Co., Ltd., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Walvax Biotech Plans to Raise up to USD72.9 Million in Private Placement of Shares 11
Walvax Biotechnology Announces Public Offering Of Notes For US$188 Million 12
Walvax Biotechnology Plans Debt Offering For US$398 Million 13
Walvax Biotechnology Announces Public Offering Of Bonds For US$158 Million 14
Walvax Biotech to Divest Kerry and Bio-Pharma and Heyzer Run Biotech for USD82 Million 15
Walvax Biotech to Sell 46% Stake in Hebei Da'an Pharma for USD103 Million 16
Walvax Biotech Plans to Acquire 51% Stake in Chongqing times Ning for USD29 Million 17
Walvax Biotech Receives Approval to Acquire Chongqing Beining Biological Pharma for USD57 Million 18
Walvax Biotech Acquires Three Biomedical Companies 19
Walvax Biotechnology To Acquire 63.57% Stake In Genor BioPharma From Shihezi Ansheng Investment And Wison Group For US$47.5 Million 20
Walvax Biotechnology To Acquire Ningbo Biological Medicine Company For US$48.5 Million 22
Walvax Biotechnology To Acquire Putian Pharma Company For US$26.3 Million 23
Walvax Biotechnology To Acquire Shandong Biological Medicine Company For US$48.5 Million 24
Walvax Biotechnology Acquires 40.61% Stake In Shanghai Biotech Company For US$19.7 Million 25
Walvax Biotechnology To Acquire Additional 35% Stake In Hebei Da'an Pharma For US$54.6 Million 26
Yunnan Walvax Acquires 58% Stake In Shanghai Zerun Biotech For US$49 Million 27
Walvax Biotechnology Completes Acquisition Of 55% Stake In Hebei Da'an Pharma For Up To US$84 Million 29
Walvax Biotechnology Co., Ltd., Key Competitors 30
Walvax Biotechnology Co., Ltd., Subsidiaries 31
List of Figures
Walvax Biotechnology Co., Ltd., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Walvax Biotechnology Co., Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Walvax Biotechnology Co., Ltd., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Walvax Biotechnology Co., Ltd., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Walvax Biotechnology Co., Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Walvax Biotechnology Co., Ltd., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Walvax Biotechnology Co., Ltd., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Walvax Biotechnology Co., Ltd., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
